- Previous Close
1.3700 - Open
1.3500 - Bid 1.3700 x --
- Ask 1.3800 x --
- Day's Range
1.3300 - 1.3800 - 52 Week Range
1.1300 - 1.6800 - Volume
11,918,840 - Avg. Volume
14,210,874 - Market Cap (intraday)
2.75B - Beta (5Y Monthly) 0.20
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0900 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Aug 7, 2018
- 1y Target Est
--
Zhongzhu Healthcare Holding Co.,Ltd engages in the research, development, production, and sales of pharmaceuticals drugs in China. It offers ophthalmology drugs, including pearl eye drops, sodium cromoglycate eye drops solution, acyclovir eye drops, hydroxybenzazole hydrochloride eye drops, acyclovir dispersible tablets, gatifloxacin tablets, etc. It is also involved in production and sales of products, including hepatest ultrasonic liver cirrhosis detector, infusion heater, Luna God full-body gamma knife, etc. In addition, the company engages in residential real estate development, capital market services, technology promotion and application service, medical services and devices, special equipment manufacturing, software and information technology service, hospital investment management, leasing and business services. The company researches and develops drugs, such as Genistein capsule which has completed the phase 2 clinical research for the prevention and treatment of women's menopausal syndrome, osteoporosis, and anti-tumor effect; Leonurine sulfate tablets, which has completed phase 1b clinical study for the prevention and treatment of cardiovascular and cerebrovascular diseases and strokes; and motherwort. The company was formerly known as Zhongzhu Holding Co., Ltd. and changed its name to Zhongzhu Healthcare Holding Co., Ltd in June 2016. The company was founded in 1970 and is headquartered in Zhuhai, China.
www.zz600568.com1,430
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 600568.SS
View MorePerformance Overview: 600568.SS
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 600568.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 600568.SS
View MoreValuation Measures
Market Cap
2.75B
Enterprise Value
2.38B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.30
Price/Book (mrq)
1.21
Enterprise Value/Revenue
3.71
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-28.00%
Return on Assets (ttm)
-7.03%
Return on Equity (ttm)
-7.06%
Revenue (ttm)
641.61M
Net Income Avi to Common (ttm)
-179.65M
Diluted EPS (ttm)
-0.0900
Balance Sheet and Cash Flow
Total Cash (mrq)
383.28M
Total Debt/Equity (mrq)
0.68%
Levered Free Cash Flow (ttm)
199.97M